JP7631319B2 - 治療方法 - Google Patents

治療方法 Download PDF

Info

Publication number
JP7631319B2
JP7631319B2 JP2022514215A JP2022514215A JP7631319B2 JP 7631319 B2 JP7631319 B2 JP 7631319B2 JP 2022514215 A JP2022514215 A JP 2022514215A JP 2022514215 A JP2022514215 A JP 2022514215A JP 7631319 B2 JP7631319 B2 JP 7631319B2
Authority
JP
Japan
Prior art keywords
alkyl
substituted
halo
inhibitor
pde1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022514215A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022546711A5 (https=
JP2022546711A (ja
Inventor
リ，ポン
デイビス，ロバート
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intra Cellular Therapies Inc
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of JP2022546711A publication Critical patent/JP2022546711A/ja
Publication of JP2022546711A5 publication Critical patent/JP2022546711A5/ja
Application granted granted Critical
Publication of JP7631319B2 publication Critical patent/JP7631319B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022514215A 2019-09-03 2020-09-03 治療方法 Active JP7631319B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962895476P 2019-09-03 2019-09-03
US62/895,476 2019-09-03
PCT/US2020/049248 WO2021046250A1 (en) 2019-09-03 2020-09-03 Methods of treatment

Publications (3)

Publication Number Publication Date
JP2022546711A JP2022546711A (ja) 2022-11-07
JP2022546711A5 JP2022546711A5 (https=) 2023-08-21
JP7631319B2 true JP7631319B2 (ja) 2025-02-18

Family

ID=74853030

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022514215A Active JP7631319B2 (ja) 2019-09-03 2020-09-03 治療方法

Country Status (11)

Country Link
US (1) US12599603B2 (https=)
EP (1) EP4025218A4 (https=)
JP (1) JP7631319B2 (https=)
KR (1) KR20220054853A (https=)
CN (1) CN114340636A (https=)
AU (1) AU2020343329C1 (https=)
BR (1) BR112022003670A2 (https=)
CA (1) CA3147071A1 (https=)
IL (1) IL290983A (https=)
MX (1) MX2022002607A (https=)
WO (1) WO2021046250A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020146384A1 (en) 2019-01-07 2020-07-16 Intra-Cellular Therapies, Inc. Organic compounds
KR20220054853A (ko) 2019-09-03 2022-05-03 인트라-셀룰라 써래피스, 인코퍼레이티드. 치료 방법
MX2024010993A (es) * 2022-03-11 2024-09-17 Intra Cellular Therapies Inc Compuestos organicos.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016022893A1 (en) 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Organic compounds

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690935A (en) 1983-03-31 1987-09-01 Wayne State University Inhibition of tumor growth and metastasis with calcium channel blocker compounds
AU2006255028B2 (en) 2005-06-06 2012-04-19 Intra-Cellular Therapies, Inc. Organic compounds
KR20120012831A (ko) 2007-12-06 2012-02-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
KR20110103949A (ko) 2008-12-06 2011-09-21 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
MA32942B1 (fr) * 2008-12-06 2012-01-02 Intra Cellular Therapies Inc Composes organiques
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
WO2012177263A1 (en) 2011-06-24 2012-12-27 Intra-Cellular Therapies, Inc. Compounds and methods of prophylaxis and treatment regarding nictonic receptor antagonists
JP6224597B2 (ja) 2011-09-27 2017-11-01 バイオメッド バレー ディスカバリーズ，インコーポレイティド グリオーマを処置するための組成物及び方法
WO2013138118A1 (en) 2012-03-14 2013-09-19 The Regents Of The University Of California Treatment of inflammatory disorders in non-human mammals
CA2877146C (en) 2012-06-18 2020-10-20 Dart Neuroscience (Cayman) Ltd Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds
EP2968338B1 (en) 2013-03-15 2019-01-09 Intra-Cellular Therapies, Inc. Pde1 inhibitors for use in the treatment and/or prevention of cns injuries, and pns diseases, disorders or injuries
KR102240326B1 (ko) 2013-03-15 2021-04-13 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
JP6696904B2 (ja) 2014-01-08 2020-05-20 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 製剤および医薬組成物
EP3157926B1 (en) 2014-06-20 2019-05-15 Intra-Cellular Therapies, Inc. Organic compounds
CA2961212C (en) 2014-09-17 2024-02-06 Intra-Cellular Therapies, Inc. Compounds and methods
US10849862B2 (en) * 2014-12-26 2020-12-01 Theravalues Corporation Formulation of curcumin and anti-PD-1 antibody
JP2018515474A (ja) 2015-04-28 2018-06-14 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置
CA2991628C (en) 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
KR20180105685A (ko) * 2016-02-08 2018-09-28 비욘드스프링 파마수티컬스, 인코포레이티드. 투카레솔 또는 이의 유사체를 함유하는 조성물
JP7134168B6 (ja) 2016-09-12 2024-02-02 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用
WO2018093591A1 (en) 2016-11-03 2018-05-24 Juno Therapeutics, Inc. Combination therapy of a cell based therapy and a microglia inhibitor
EP3558319A4 (en) 2016-12-22 2020-07-22 AbbVie Inc. COMPOSITIONS AND PROCESSES FOR IMPROVING OR INCREASING THE PRODUCTION OF TYPE I IFN
EP3612839A1 (en) 2017-04-20 2020-02-26 ADC Therapeutics SA Combination therapy
TW201920104A (zh) 2017-08-31 2019-06-01 美商馬愈法瑪公司 外核苷酸焦磷酸酶-磷酸二酯酶1(enpp-1)抑制劑及其用途
US20210338679A1 (en) 2018-09-25 2021-11-04 Intra-Cellular Therapies, Inc. Novel uses
WO2020146384A1 (en) * 2019-01-07 2020-07-16 Intra-Cellular Therapies, Inc. Organic compounds
KR20220054853A (ko) 2019-09-03 2022-05-03 인트라-셀룰라 써래피스, 인코퍼레이티드. 치료 방법
MX2024010993A (es) 2022-03-11 2024-09-17 Intra Cellular Therapies Inc Compuestos organicos.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016022893A1 (en) 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Organic compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Cancer Letters，2007年，Vol.255，pp.170-181
Eur. J. Med. Chem.，2018年，Vol. 150，pp. 742-756
J for ImmunoTherapy of Cancer，2014年，Vol.2, Suppl 3，p.210

Also Published As

Publication number Publication date
IL290983A (en) 2022-05-01
WO2021046250A1 (en) 2021-03-11
AU2020343329C1 (en) 2026-02-12
JP2022546711A (ja) 2022-11-07
AU2020343329A1 (en) 2022-03-24
US20220354851A1 (en) 2022-11-10
EP4025218A1 (en) 2022-07-13
BR112022003670A2 (pt) 2022-05-24
MX2022002607A (es) 2022-03-25
KR20220054853A (ko) 2022-05-03
CN114340636A (zh) 2022-04-12
CA3147071A1 (en) 2021-03-11
US12599603B2 (en) 2026-04-14
AU2020343329B2 (en) 2025-07-24
EP4025218A4 (en) 2023-05-31

Similar Documents

Publication Publication Date Title
JP7564172B2 (ja) 免疫チェックポイント阻害薬と併用するプリナブリンの使用
JP7543278B2 (ja) 有機化合物
JP7631319B2 (ja) 治療方法
JP2024513505A (ja) 腫瘍を治療するための組成物及び方法
US20250073230A1 (en) Use of plinabulin in combination with immune checkpoint inhibitors
US20250186446A1 (en) Organic compounds
JP7493460B2 (ja) 有機化合物
RU2822394C1 (ru) Способы лечения
HK40066948A (zh) 治疗方法
CN118922191A (zh) 有机化合物
HK40112650A (zh) 有机化合物
HK40102238A (zh) 用於治疗肿瘤的治疗组合物和方法
BR112017016902B1 (pt) Composição farmacêutica, respectivo uso e uso de plinabulina
NZ750444B2 (en) Use of plinabulin in combination with immune checkpoint inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230810

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230810

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241202

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250121

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250205

R150 Certificate of patent or registration of utility model

Ref document number: 7631319

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150